Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:56:03.222Z.
Consensus retrieved: 2026-10-06T10:42:49.591Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:03.222Z.
Quote observation: 2026-10-06T15:55:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7917a7cc8c7b4e75475caf5d3db61bffcb49ffeef440a300017a50834728fbad
Forward PE Ratio (N/A) = Dated Quote Price ($61.88) / Consensus Forward EPS ($-6.05)
FORWARD PE RATIO
N/A
Cytokinetics, Incorporated
Market Cap
$7.70B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cytokinetics, Incorporated (CYTK) | $7.70B | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.66B | 19.40 |
| Hinge Health, Inc. (HNGE)vs › | $7.58B | 42.23 |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.84B | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.39B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $8.11B | 247.34 |
| Alkermes plc (ALKS)vs › | $7.08B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 17.00 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.67B | N/A |
| Chemed Corporation (CHE)vs › | $6.68B | 20.04 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $61.88, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-6.05 | $-6.46 – $-4.11 | 15 | n/m |
| 2027-12-31 | $-4.48 | $-5.38 – $-3.03 | 15 | n/m |
| 2028-12-31 | $-2.11 | $-4.06 – $-0.22 | 14 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
